Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Mammoth Biosciences is a private biotechnology company developing ultracompact CRISPR systems for in vivo gene-editing therapeutics, molecular diagnostics, and protein discovery. Its platform is designed to overcome delivery and targeting constraints of larger CRISPR systems and support editing modalities beyond conventional double-strand breaks.
Primary product
Ultracompact CRISPR-based gene-editing platform, including NanoCas/CasΦ systems; lead internal therapeutic program MB-111 targets APOC3 for familial chylomicronemia syndrome and severe hypertriglyceridemia. Mammoth also develops the DETECTR molecular-diagnostics platform.
Founded
2017
Headquarters
1000 Marina Blvd., Suite 600, Brisbane, California 94005, United States
Team size
100-150
Work style
Hybrid
Industry
Biotechnology
Sub-industry
CRISPR gene editing, genetic medicines, molecular diagnostics, and protein engineering
Offices
Business model
Stage
Late-stage private biotechnology company; reported unicorn valuation after its 2021 Series D
Total raised
$465M
Latest round
Regeneron corporate investment and collaboration · Apr 2024
Latest amount
$100M
Regeneron corporate investment and upfront payment
Apr 2024 · Regeneron Pharmaceuticals
Vertex convertible note and strategic investment
Oct 2021 · Vertex Pharmaceuticals
Sep 2021 · Redmile Group
Jan 2020 · Decheng Capital
Jan 2020 · Redmile Group and Foresite Capital
Jul 2018 · Mayfield
Pre-seed / NFX accelerator financing
Jan 2017 · NFX
Leadership
Co-founder and Chief Executive Officer
Co-founder, Chief Scientific Officer and President, Research
Jennifer Doudna
Co-founder and Chair of the Scientific Advisory Board
Lucas Harrington
Co-founder
Chief Financial Officer and Chief Operating Officer
Gabor Veres
Vice President, Translational Sciences
Aruna Perera
Vice President, Technical Operations
Sandeep Soni
Vice President, Clinical Development
Siang Chin
Head of Alliance Management
Investors
The company describes its culture around scientific discovery, patient impact, intelligent risk-taking, urgency, accountability, diversity, inclusion, and cross-functional collaboration. Its careers materials emphasize a supportive community, employee resource groups, and a lab-centered workplace in Brisbane.
Work style
Hybrid
Visa sponsorship
Yes
Compensation
Public job postings show example base-salary ranges of $142,000-$178,000 for a Senior Clinical Scientist and $110,000-$137,000 for a Senior Analyst, FP&A. Public labor-filing aggregators report H-1B sponsorship activity and a median certified H-1B base salary of approximately $119,498 for FY2021-FY2025. Actual eligibility and sponsorship vary by role.
Benefits
Pricing
Not publicly disclosed; therapeutic programs are funded through partnerships, equity, upfront payments, milestones, royalties, and potential profit-sharing. Diagnostic-product pricing is not publicly disclosed.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M based on a third-party estimate; other commercial databases publish materially higher estimates, so this figure is low confidence.
Estimated monthly visits
14K
Mammoth confirmed a restructuring or strategic-alignment action that eliminated 24 roles. CEO Trevor Martin said the company was focusing on having the right organization to advance internal programs into the clinic, support partnerships, and continue research.
SourceThe company shifted strategic emphasis from its original diagnostics focus toward therapeutic development, particularly in vivo gene editing. This creates normal biotech-development, regulatory, clinical, and financing risks because the lead programs remain investigational.
SourceMammoth Biosciences newsroom · Jan 2025
Mammoth announced MB-111 as its first development candidate and added genetic-medicines veteran Bob D. Brown to its board, signaling increased focus on moving the internal pipeline toward clinical development.
Reuters · Apr 2024
Regeneron and Mammoth announced a collaboration combining Regeneron's targeted AAV delivery with Mammoth's ultracompact CRISPR systems. Mammoth receives $100 million upfront and equity consideration and may receive up to $370 million per target plus royalties.
Reuters · Jan 2022
Bayer agreed to collaborate with Mammoth on in vivo gene-editing therapies, providing $40 million upfront and potential milestone payments exceeding $1 billion.
Business Wire · Sep 2021
Mammoth announced a $150 million Series D led by Redmile Group, following a $45 million Series C, bringing the combined financing announced in 2020 and 2021 to $195 million and the company to a reported valuation above $1 billion.
1 job at Mammoth Biosciences